HC Wainwright Predicts Stronger Earnings for Bausch + Lomb

Bausch + Lomb Corporation (NYSE:BLCO) – Stock analysts at HC Wainwright boosted their Q1 2027 earnings estimates for shares of Bausch + Lomb in a report issued on Monday, August 3rd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $0.12 for the quarter, up from their prior forecast of $0.07. HC Wainwright currently has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q2 2027 earnings at $0.25 EPS, Q3 2027 earnings at $0.21 EPS, Q4 2027 earnings at $0.31 EPS and FY2027 earnings at $0.89 EPS.

Several other research firms have also recently weighed in on BLCO. Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft set a $16.00 price target on shares of Bausch + Lomb in a research note on Thursday, April 30th. Evercore set a $17.00 price objective on Bausch + Lomb in a report on Monday, July 6th. UBS Group assumed coverage on Bausch + Lomb in a research report on Thursday. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, Citigroup boosted their target price on Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Five analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $18.75.

Bausch + Lomb Stock Performance

Shares of NYSE:BLCO opened at $16.79 on Tuesday. The business has a fifty day moving average of $15.95 and a 200-day moving average of $16.42. The firm has a market cap of $5.99 billion, a PE ratio of -34.98, a price-to-earnings-growth ratio of 0.52 and a beta of 0.55. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.02 and a current ratio of 1.55. Bausch + Lomb has a twelve month low of $13.53 and a twelve month high of $18.92.

Hedge Funds Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers raised its position in Bausch + Lomb by 3.9% in the 4th quarter. Cetera Investment Advisers now owns 18,713 shares of the company’s stock valued at $320,000 after buying an additional 711 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Bausch + Lomb by 38.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,757 shares of the company’s stock worth $64,000 after buying an additional 1,039 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in shares of Bausch + Lomb by 5.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock valued at $364,000 after acquiring an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in Bausch + Lomb by 104.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after purchasing an additional 1,136 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after purchasing an additional 1,403 shares during the last quarter. Institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.